Cargando…

The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1

Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) is an inherited arrhythmogenic disorder caused by missense mutations in the cardiac ryanodine receptors (RyR2), that result in increased β‐adrenoceptor stimulation‐induced diastolic Ca(2+) leak. We have previously shown that exerci...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadredini, Mani, Manotheepan, Ravinea, Lehnart, Stephan E., Anderson, Mark E., Sjaastad, Ivar, Stokke, Mathis K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461029/
https://www.ncbi.nlm.nih.gov/pubmed/34558218
http://dx.doi.org/10.14814/phy2.15030
_version_ 1784571888681353216
author Sadredini, Mani
Manotheepan, Ravinea
Lehnart, Stephan E.
Anderson, Mark E.
Sjaastad, Ivar
Stokke, Mathis K.
author_facet Sadredini, Mani
Manotheepan, Ravinea
Lehnart, Stephan E.
Anderson, Mark E.
Sjaastad, Ivar
Stokke, Mathis K.
author_sort Sadredini, Mani
collection PubMed
description Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) is an inherited arrhythmogenic disorder caused by missense mutations in the cardiac ryanodine receptors (RyR2), that result in increased β‐adrenoceptor stimulation‐induced diastolic Ca(2+) leak. We have previously shown that exercise training prevents arrhythmias in CPVT1, potentially by reducing the oxidation of Ca(2+)/calmodulin‐dependent protein kinase type II (CaMKII). Therefore, we tested whether an oxidation‐resistant form of CaMKII protects mice carrying the CPVT1‐causative mutation RyR2‐R2474S (RyR2‐RS) against arrhythmias. Antioxidant treatment (N‐acetyl‐L‐cysteine) reduced the frequency of β‐adrenoceptor stimulation‐induced arrhythmogenic Ca(2+) waves in isolated cardiomyocytes from RyR2‐RS mice. To test whether the prevention of CaMKII oxidation exerts an antiarrhythmic effect, mice expressing the oxidation‐resistant CaMKII‐MM281/282VV variant (MMVV) were crossed with RyR2‐RS mice to create a double transgenic model (RyR2‐RS/MMVV). Wild‐type mice served as controls. Telemetric ECG surveillance revealed an increased incidence of ventricular tachycardia and an increased arrhythmia score in both RyR2‐RS and RyR2‐RS/MMVV compared to wild‐type mice, both following a β‐adrenoceptor challenge (isoprenaline i.p.), and following treadmill exercise combined with a β‐adrenoceptor challenge. There were no differences in the incidence of arrhythmias between RyR2‐RS and RyR2‐RS/MMVV mice. Furthermore, no differences were observed in β‐adrenoceptor stimulation‐induced Ca(2+) waves in RyR2‐RS/MMVV compared to RyR2‐RS. In conclusion, antioxidant treatment reduces β‐adrenoceptor stimulation‐induced Ca(2+) waves in RyR2‐RS cardiomyocytes. However, oxidation‐resistant CaMKII‐MM281/282VV does not protect RyR2‐RS mice from β‐adrenoceptor stimulation‐induced Ca(2+) waves or arrhythmias. Hence, alternative oxidation‐sensitive targets need to be considered to explain the beneficial effect of antioxidant treatment on Ca(2+) waves in cardiomyocytes from RyR2‐RS mice.
format Online
Article
Text
id pubmed-8461029
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84610292021-09-28 The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1 Sadredini, Mani Manotheepan, Ravinea Lehnart, Stephan E. Anderson, Mark E. Sjaastad, Ivar Stokke, Mathis K. Physiol Rep Original Articles Catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) is an inherited arrhythmogenic disorder caused by missense mutations in the cardiac ryanodine receptors (RyR2), that result in increased β‐adrenoceptor stimulation‐induced diastolic Ca(2+) leak. We have previously shown that exercise training prevents arrhythmias in CPVT1, potentially by reducing the oxidation of Ca(2+)/calmodulin‐dependent protein kinase type II (CaMKII). Therefore, we tested whether an oxidation‐resistant form of CaMKII protects mice carrying the CPVT1‐causative mutation RyR2‐R2474S (RyR2‐RS) against arrhythmias. Antioxidant treatment (N‐acetyl‐L‐cysteine) reduced the frequency of β‐adrenoceptor stimulation‐induced arrhythmogenic Ca(2+) waves in isolated cardiomyocytes from RyR2‐RS mice. To test whether the prevention of CaMKII oxidation exerts an antiarrhythmic effect, mice expressing the oxidation‐resistant CaMKII‐MM281/282VV variant (MMVV) were crossed with RyR2‐RS mice to create a double transgenic model (RyR2‐RS/MMVV). Wild‐type mice served as controls. Telemetric ECG surveillance revealed an increased incidence of ventricular tachycardia and an increased arrhythmia score in both RyR2‐RS and RyR2‐RS/MMVV compared to wild‐type mice, both following a β‐adrenoceptor challenge (isoprenaline i.p.), and following treadmill exercise combined with a β‐adrenoceptor challenge. There were no differences in the incidence of arrhythmias between RyR2‐RS and RyR2‐RS/MMVV mice. Furthermore, no differences were observed in β‐adrenoceptor stimulation‐induced Ca(2+) waves in RyR2‐RS/MMVV compared to RyR2‐RS. In conclusion, antioxidant treatment reduces β‐adrenoceptor stimulation‐induced Ca(2+) waves in RyR2‐RS cardiomyocytes. However, oxidation‐resistant CaMKII‐MM281/282VV does not protect RyR2‐RS mice from β‐adrenoceptor stimulation‐induced Ca(2+) waves or arrhythmias. Hence, alternative oxidation‐sensitive targets need to be considered to explain the beneficial effect of antioxidant treatment on Ca(2+) waves in cardiomyocytes from RyR2‐RS mice. John Wiley and Sons Inc. 2021-09-23 /pmc/articles/PMC8461029/ /pubmed/34558218 http://dx.doi.org/10.14814/phy2.15030 Text en © 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Sadredini, Mani
Manotheepan, Ravinea
Lehnart, Stephan E.
Anderson, Mark E.
Sjaastad, Ivar
Stokke, Mathis K.
The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1
title The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1
title_full The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1
title_fullStr The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1
title_full_unstemmed The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1
title_short The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1
title_sort oxidation‐resistant camkii‐mm281/282vv mutation does not prevent arrhythmias in cpvt1
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461029/
https://www.ncbi.nlm.nih.gov/pubmed/34558218
http://dx.doi.org/10.14814/phy2.15030
work_keys_str_mv AT sadredinimani theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT manotheepanravinea theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT lehnartstephane theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT andersonmarke theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT sjaastadivar theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT stokkemathisk theoxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT sadredinimani oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT manotheepanravinea oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT lehnartstephane oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT andersonmarke oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT sjaastadivar oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1
AT stokkemathisk oxidationresistantcamkiimm281282vvmutationdoesnotpreventarrhythmiasincpvt1